Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-272 PK in Renal or Hepatic Impairment
NCT02367872Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imarikiren in hypertension (HTN), heart failure (HF), chronic kidney disease (CKD) and 1 more (8 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration, Maximum Observed Plasma Concentration and 10 more. Started Mar 2015; status: completed.
02
Drugs
imarikiren
03
Conditions
hypertension (HTN)heart failure (HF)chronic kidney disease (CKD)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02367872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367872.